Integrated Advisors Network LLC Sells 1,746 Shares of Eli Lilly and Company $LLY

Key Points

• Integrated Advisors Network reduced its Eli Lilly stake by 11.9%, selling 1,746 shares in the third quarter and retaining 12,891 shares worth approximately $14.9 million. Institutional investors and hedge funds collectively own 82.53% of the stock.
• Eli Lilly reported strong quarterly results, with EPS of $8.38 exceeding estimates of $6.40 and revenue rising 47.7% year over year to $22.97 billion. The stock traded near its 52-week high at $1,308.21, with a market capitalization of roughly $1.23 trillion.
• Analysts remain broadly positive, giving Eli Lilly a consensus “Moderate Buy” rating and an average price target of $1,317.93, although pricing pressure and intensifying obesity-drug competition remain risks. Recent insider sales were conducted under pre-arranged Rule 10b5-1 plans.

Integrated Advisors Network LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 11.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,891 shares of the company's stock after selling 1,746 shares during the period. Eli Lilly and Company accounts for approximately 0.7% of Integrated Advisors Network LLC's holdings, making the stock its 25th biggest holding. Integrated Advisors Network LLC's holdings in Eli Lilly and Company were worth $14,916,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Integrity Financial Corp WA boosted its holdings in Eli Lilly and Company by 1.3% in the second quarter. Integrity Financial Corp WA now owns 639 shares of the company's stock valued at $767,000 after acquiring an additional 8 shares during the last quarter. LCM Capital Management Inc grew its position in Eli Lilly and Company by 3.3% during the third quarter. LCM Capital Management Inc now owns 253 shares of the company's stock valued at $293,000 after acquiring an additional 8 shares during the period. Willner & Heller LLC grew its position in Eli Lilly and Company by 1.0% during the second quarter. Willner & Heller LLC now owns 917 shares of the company's stock valued at $1,100,000 after acquiring an additional 9 shares during the period. Aspiring Ventures LLC increased its stake in Eli Lilly and Company by 3.7% during the second quarter. Aspiring Ventures LLC now owns 255 shares of the company's stock worth $306,000 after acquiring an additional 9 shares during the last quarter. Finally, Wealthspan Partners LLC increased its stake in Eli Lilly and Company by 0.4% during the second quarter. Wealthspan Partners LLC now owns 2,120 shares of the company's stock worth $2,543,000 after acquiring an additional 9 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,308.21 on Friday. The firm has a market capitalization of $1.23 trillion, a PE ratio of 43.90, a price-to-earnings-growth ratio of 1.69 and a beta of 0.46. Eli Lilly and Company has a one year low of $806.02 and a one year high of $1,321.21. The stock's 50 day moving average price is $1,184.78 and its 200 day moving average price is $1,119.15. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter last year, the company earned $6.31 earnings per share. Eli Lilly and Company's revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 33.56 EPS for the current fiscal year.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: GLP-1 leadership remains the central growth catalyst. Lilly’s Mounjaro and Zepbound franchises continue to drive explosive growth in cardiometabolic and incretin medicines, strengthening the bull case relative to more diversified peers such as Amgen and Bristol Myers Squibb. Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
• Positive Sentiment: Lilly is expanding production capacity. The company broke ground on a $5 billion Richmond, Virginia, facility as part of a more than $50 billion U.S. manufacturing build-out. The integrated site will produce active ingredients and finished medicines, including next-generation cancer treatments, and is expected to create 650 jobs. The investment could help Lilly meet demand while reducing supply constraints. Lilly breaks ground in Richmond
• Positive Sentiment: International manufacturing and logistics deals add scale. Partnerships involving Abu Dhabi-based Mubadala Bio are expected to support local packaging, logistics and contract manufacturing for Lilly’s GLP-1 medicines, improving regional distribution and market access. Lilly and Mubadala Bio sign deal
• Neutral Sentiment: Upcoming quarterly results are the next major test. Lilly is scheduled to report earnings Thursday, with investors focused on sales growth, prescription volume, pricing, supply and updated guidance. The stock’s strong run and elevated valuation increase the potential for volatility around the report. Earnings Preview: Eli Lilly Q3 Earnings Expected to Decline
• Negative Sentiment: Profitability could face pricing pressure. In the second quarter, revenue grew 48% on a 60% increase in medicine volume, but average realized prices fell 13%. This suggests Lilly must sustain exceptional volume growth to offset lower pricing, a concern ahead of its results. Eli Lilly Grew Revenue 48% While Prices Fell
• Negative Sentiment: Competition in obesity drugs is intensifying. Novo Nordisk’s CagriSema produced substantial weight-loss results, highlighting a potential competitive threat to Lilly’s GLP-1 dominance and reinforcing concerns that the stock’s premium valuation already reflects significant future growth. Obesity ETFs to Gain as Novo’s CagriSema Shows 25% Weight Loss

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Wall Street Zen downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Saturday, October 17th. Cantor Fitzgerald boosted their target price on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an "overweight" rating in a report on Thursday, October 8th. The Goldman Sachs Group reiterated a "buy" rating and set a $1,413.00 target price on shares of Eli Lilly and Company in a report on Tuesday. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Finally, JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an "overweight" rating in a report on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average target price of $1,317.93.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald Zakrowski sold 2,000 shares of the company's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company's stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.